All Updates

All Updates

icon
Filter
Funding
Healx raises USD 47 million in Series C funding to advance pipeline programs
AI Drug Discovery
Aug 1, 2024
This week:
Partnerships
T-Mobile partners with OpenAI to develop AI-powered customer service platform
Generative AI Applications
Yesterday
Partnerships
Runway partners with Lionsgate to develop AI video tools using studio's movie catalog
Generative AI Applications
Sep 18, 2024
Funding
QMill raises EUR 4 million in seed funding to provide quantum computing industrial applications
Quantum Computing
Sep 18, 2024
Product updates
QuiX Quantum launches 'Bia' quantum cloud computing service for quantum solutions
Quantum Computing
Sep 18, 2024
Partnerships
Oxford Ionics and Infineon Technologies partner to build portable quantum computer for Cyberagentur
Quantum Computing
Sep 18, 2024
Product updates
Partnerships
Tencent Ai Lab launches EzAudio AI for text-to-audio generation with Johns Hopkins University
Foundation Models
Sep 18, 2024
Funding
TON secures USD 30 million in investment from Bitget and Foresight Ventures
Web3 Ecosystem
Sep 18, 2024
Funding
Hemi Labs raises USD 15 million in funding to launch blockchain network
Web3 Ecosystem
Sep 18, 2024
Product updates
Fivetran launches Hybrid Deployment for data pipeline management
Machine Learning Infrastructure
Sep 18, 2024
Product updates
Fivetran launches Hybrid Deployment for data pipeline management
Data Infrastructure & Analytics
Sep 18, 2024
AI Drug Discovery

AI Drug Discovery

Aug 1, 2024

Healx raises USD 47 million in Series C funding to advance pipeline programs

Funding

  • UK-based AI-powered biotechnology company Healx has raised USD 47 million in a Series C funding round co-led by R42 Group and Atomico, with contributions from other investors including Balderton, Jonathan Milner, Global Brain, btov, Ayana Capital, o2h, and VU Venture Partners.

  • The company plans to use the funds to advance its pipeline of medicines in rare oncology, renal, and neurodevelopmental disorders. This will include its lead program, HLX-1502, aimed at treating neurofibromatosis type 1 (NF1).

  • The program has received clearance from the FDA to proceed with a Phase II clinical trial, expected to commence in late 2024.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.